上海醫藥集團股份有限公司
Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

2020 FIRST QUARTERLY REPORT

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following is the first quarterly report for 2020 of Shanghai Pharmaceuticals Holding Co., Ltd.. The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By order of the Board
Shanghai Pharmaceuticals Holding Co., Ltd.*
ZHOU Jun
Chairman

Shanghai, the PRC, 29 April 2020

As at the date of this announcement, the executive directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the independent non-executive directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.

* *For identification purpose only*

I. IMPORTANT NOTICE

1.1 The board of directors and the board of supervisors of the Company and the directors, supervisors and senior management shall warrant that the contents of this quarterly report are true, accurate and complete and contain no false information, misleading statement or material omission and assume several and joint legal responsibilities therefor.

1.2 All directors of the Company attended the eleventh meeting of the seven session of the board of directors held on 28 April 2020, at which resolutions including the first quarterly results of the Company for the three months ended 31 March 2020 were approved.

1.3 ZHOU Jun, the person in charge of the Company, CHO Man, the principal in charge of accounting and SHEN Bo, the head of the accounting department (Chief Financial Officer), hereby declare that they warrant the truthfulness, accuracy and completeness of the financial statements contained in this quarterly report.

1.4 The first quarterly report of the Company was unaudited.

1.5 DEFINITIONS

In this report, unless the context otherwise requires, the following terms shall have the following meanings, and all the relevant financial information has been prepared in accordance with the requirements of the PRC Accounting Standards:

"the Group", "Group", "the Company", "Company" or "Shanghai Pharmaceuticals"	Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司), a joint stock company incorporated in the PRC with limited liability (the shares of which are listed on the Shanghai Stock Exchange with stock code 601607; and on the Main Board of The Stock Exchange of Hong Kong Limited with stock code 02607) or Shanghai Pharmaceuticals Holding Co., Ltd. and its subsidiaries, where applicable
"the Reporting Period", "Reporting Period" or "Period"	the 3-month period from 1 January 2020 to 31 March 2020
"YOY" or "year-on-year"	Compared with the same period of previous year
"the PRC"	the People's Republic of China; unless the context otherwise requires, references to the PRC or China in this report do not include Hong Kong, Macau or Taiwan

"Shares"	shares of Shanghai Pharmaceuticals with a nominal value of RMB1.00 each, comprising both A Shares and H Shares
"A Share(s)"	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed on the Shanghai Stock Exchange and traded in RMB
"H Share(s)"	foreign shares of the Company, with a nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars
"RMB" or "Renminbi"	Renminbi, the lawful currency of the PRC
"Hong Kong Stock Exchange"	The Stock Exchange of Hong Kong Limited
"SIIC"	Shanghai Industrial Investment (Holdings) Co., Ltd. (上海實業(集團)有限公司)
"Shanghai Shangshi"	Shanghai Shangshi (Group) Co., Ltd. (上海上實(集團)有限公司)
"Shanghai Pharmaceutical (Group)"	Shanghai Pharmaceutical (Group) Co., Ltd. (上海醫藥(集團)有限公司)
"Shanghai Guosheng"	Shanghai Guosheng Group Assets Co., Ltd. (上海國盛集團資產有限公司)
"Shanghai Shengrui"	Shanghai Shengrui Investment Co., Ltd. (上海盛睿投資有限公司)
"SPHC"	Shanghai Pharmaceuticals Grand Health Cloud Commerce Co., Ltd. (上海醫藥大健康雲商股份有限公司)
"FDA"	Food and Drug Administration of the United States
"BD"	expanded introduction of new drugs
"HIS"	Hospital information system

II. MANAGEMENT DISCUSSION AND ANALYSIS

In the first quarter of 2020, the novel coronary pneumonia epidemic broke out, temporarily changing the lifestyles of people across the country, including the way they visit the doctor and seek medical advice, which indirectly affected the Company's principal businesses of pharmaceutical manufacturing and pharmaceutical services. As the epidemic situation cleared up, the production and operation of businesses have fully recovered, economic activities have been restored in an orderly manner, and rigid demand even rebounded in some areas.

During the Reporting Period, the Company recorded an operating revenue of RMB40.448 billion (a year-on-year decrease of 12.08%). Specifically, revenue from pharmaceutical manufacturing was RMB5.651 billion (a year-on-year decrease of 8.80%) and revenue from pharmaceutical service was RMB34.797 billion (a year-on-year decrease of 12.59%). The Company recorded a net profit attributable to shareholders of the listed company of RMB1.038 billion (a year-on-year decrease of 7.84%), and a net profit after deduction of non-recurring profit or loss attributable to shareholders of listed company of RMB983 million (a year-on-year decrease of 5.42%), of which the principal business of pharmaceutical manufacturing contributed profits RMB518 million (a year-on-year increase of 1.07%), the principal business of pharmaceutical service contributed profit RMB463 million (a year-on-year decrease of 9.91%), and invested companies contributed profit of RMB267 million (a year-on-year increase of 13.13%).

During the Reporting Period, the Company invested RMB341 million in R&D expenses, representing an increase of 25.93% year-on-year, and recorded net profit attributable to shareholders of the listed company after the reversal of R&D expenses and deduction of non-recurring profit or loss of RMB1.324 billion, representing an increase of 1.06% year-on-year.

During the Reporting Period, the integrated gross profit margin of the Company was 15.17%, an increase of 1.12 percentage points compared with the same period of last year; the operating profit margin net of the administrative, sales, and R&D expenses was 4.30%, an increase of 0.55 percentage point compared with the same period of last year.

In January 2020, the novel coronary pneumonia broke out. The Company had established an emergency response leading group before the Chinese New Year comprising all members of the leading team of the Company each assigned with separate duties. The subsidiaries also established emergency response working groups to combat the epidemic. With top-down coordination, the Company has created a well-coordinated and highly responsive working mechanism. To address the issues of shortage of anti-epidemic supplies and incontinent personnel movement, the Company, with foresight, quickly started global procurement of anti-epidemic supplies such as masks and protective suits and proactively carried out basic tasks such as resumption of work of employees in batches, storage and dispatch of supplies, calculation of market demands, strengthening of logistics delivery, development of production plan, reporting and preparation for early resumption of work, procurement of raw materials and packaging materials, and stocking at retail terminals. At the same time, it started a round-the-clock on-duty system to ensure timely response to instructions from the front line on production, inventory allocation and logistics transportation of anti-epidemic drugs and supplies, thereby making full use of every minute to save lives.

In terms of pharmaceutical service, the Company was faced with a very tough challenge of ensuring supplies. Warehousing and logistics employees voluntarily gave up their holidays and dauntlessly fight the epidemic. Since New Year's Eve, they have worked with the Shanghai-to-Hubei Medical Assistance Team to transport approximately 5 tonnes of medical supplies without a day's break to deliver the most needed aids to front-line medical workers and patients. Employees of the retail stores also opened up packages overnight to put the goods on the shelves, so as to save as much time as possible for citizens who queued up to buy masks, disinfectants and other anti-epidemic prevention materials and reduce the risk of gathering. The Company was also appointed by the government as the designated reserve and distribution enterprise of the epidemic-prevention and anti-epidemic drugs in many provinces and cities with its timely response mechanism, professional service team and dedication to fighting the epidemic. It undertook the important task of guaranteeing supplies and demonstrated the commitment and social responsibility of the pharmaceutical companies of a great country. To further enhance our strength in warehousing and logistics and create industry benchmarks, the Company also plans to build a comprehensive distribution service center in Baoshan, Shanghai, and has entered into a strategic agreement with the People's Government of Baoshan District in March. This is the first major move of the Company in building an upgraded medical supplies and services platforms since its identification at the end of January as Shanghai's base for ensuring anti-epidemic medical supplies and Shanghai's anti-epidemic medical supplies procurement platform.

In respect of pharmaceutical manufacturing, based on the key epidemic prevention monitoring varieties of the Ministry of Industry and Information Technology, the Company has compiled and established the Shanghai Pharmaceuticals Epidemic Prevention Drug List covering over 100 drugs in ten varieties such as anti-virus, antibiosis, glucocorticoid, antipyretic and analgesics, expectorant, antiasthmatic, immune regulation, preventive drugs, Chinese patent medicine, and Traditional Chinese Medicine decoction pieces (excluding medical devices). Faced with the surge in demand for many of these products, relevant production units have worked overtime since the Chinese New Year, dynamically adjusting and monitoring production according to the development of the epidemic situation and preparing for production expansion in advance, to fully support front-line clinical applications. The Company also contacted the suppliers in advance to ensure that the supply chain of raw materials and packaging materials ran smoothly and sufficient safety stock was guaranteed. During the period, drugs manufactured by the Company were also included in the "Diagnosis and Treatment Program for Novel Coronavirus Pneumonia", "Shanghai Expert Consensus on Comprehensive Treatment of COVID-19", and standard treatment program for COVID-19 in many regions of the country. The Company actively cooperated with the Ministry of Science and Technology and the Ministry of Industry and Information Technology to carry out clinical research on anti-epidemic drugs, tap the therapeutic potential of existing drugs, and explore cost-effective diagnosis and treatment options. As the novel coronary pneumonia epidemic gradually became a global public health issue, the overseas demands for the anti-epidemic drugs produced by the Company has soared. As of the beginning of April, we have already exported the drugs to dozens of countries and regions in the six continents, with the total sales volume exceeding the whole preceding year.

While prioritizing epidemic prevention and control at the moment, the Company is also fully promoting the resumption of work and production, taking a two-pronged approach to ensure both areas are properly handled. As of the end of February, the work commencement rate of the Company's subsidiaries exceeded 95%, and the work resumption rate of employees exceeded 90% including those working from home. As at the end of the Reporting Period, our operations have substantially returned to normal.

Pharmaceutical Manufacturing

The novel coronary pneumonia epidemic affected the operation of medical institutions at all levels, which indirectly affected the Company's drug sales and clinical research. However, the Company overcame a variety of difficulties, continued to advance R&D projects, accelerated the introduction of products and technologies and achieved a number of phased progress.

During the Reporting Period, the clinical trial applications of the Company's self-developed oral, small-molecular and selective ErbB2 inhibitor SPH3261 Capsules and small-molecular anti-tumor drug SPH4336 Tablets were both accepted by the National Medical Products Administration. The Company's drug for treatment of insomnia, Zozopicone Tablets, and the hypoglycemic agent, Metformin Hydrochloride Tablets (0.5g), passed the quality and efficacy consistency evaluation of generic drugs, increasing the total number of the Company's drugs passing the evaluation to 9 varieties (11 specifications).

In respect of BD product introduction, on 28 February, the Company entered into a cooperation agreement with the Israeli pharmaceutical company Mapi Pharma to work together on the development of two prolonged-action injection projects to create a prolonged-action sustained-release preparation platform with high technical barriers. In early March, the Company entered into a commissioned technology development agreement with Beijing Kexin Bicheng Medicine Science & Technology Developing Co., Ltd. (北京科信必成醫藥科技發展有限公司), a new drug research and development company, for the treatment of rare diseases. As one of the founding members of the China Alliance for Rare Disease and one of the domestic companies with the most approvals for rare disease drugs, the Company will continue to expand its R&D and product pipeline for rare disease drugs and, through project cooperation, accumulate clinical, registration and promotion experience in the field of rare diseases to build a professional rare disease drug platform integrating research, production and sales.

During the Reporting Period, the Company also determined to invest US$2.5 million to continue the co-investment in the private placement of Oncternal, an invested company of the Company, on the Nasdaq in the United States to assist in the promotion of clinical trials of pipeline products including Cirmtuzumab and TK216. The preliminary published data on enrolled patients shows that Cirmtuzumab, whether used alone or in combination with Ibutinib, has shown impressive results in clinical trials for the treatment of solid tumors such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and HER2 negative breast cancer. In particular, in phase II clinical trial of combined treatment of CLL, the total remission rate of the enrolled patients exceeded 80%. TK216 has also obtained the US FDA's orphan drug designation and rapid review channel qualification. Phase I clinical trial demonstrated its sound tolerability.

Pharmaceutical Services

On 4 March, Shanghai Renji Internet Hospital officially went live, fully ushering in an era of online medical treatment by 3A hospitals. As a partner of Renji Hospital, SPHC has completed the home delivery of the drugs for the first prescription of the Internet hospital. "Internet Hospital + Drug Home Delivery Service" not only meets the medical needs of the people, but also reduces nosocomial infections, enabling patients to access at home services such as online consultation, doctor prescription, online medical insurance payment, and direct home delivery of drugs with a mobile phone. The information system of SPHC is directly connected to the Internet Hospital's HIS system, which enables orderly undertaking of prescription outflows from medical institutions at all levels, achieving an open, highly-regulated, and traceable closed loop of diagnosis and treatment information. Taking advantage of the policy tail wind, "Internet + Medical Care" has been accessible for thousands of households.

On 18 March, the B-round financing of SPHC officially kicked off. Since its establishment, with the full support of all shareholders, SPHC has make continuous efforts in strategy, capital and operation, creating an industry-leading "Yiyao" ecosystem and gradually becoming the leader of the new economy of medical and health.

2.1 Major financial information

Unit: RMB

	As at the end of the Reporting Period	**As at the end of last year**	**Increase/decrease as at the end of the Reporting Period as compared with the end of previous year (%)**
Total assets	141,282,814,027.07	137,026,395,859.72	3.11
Net assets attributable to shareholders of listed company	42,616,426,487.68	41,659,054,746.92	2.30
	From the beginning of the year to the end of the Reporting Period	**From the beginning of the previous year to the end of the previous reporting period**	**Change compared to the corresponding period of last year (%)**
Net cash flows from operating activities	-592,090,019.55	153,660,971.11	/
	From the beginning of the year to the end of the Reporting Period	**From the beginning of the previous year to the end of the previous reporting period**	**Change compared to the corresponding period of last year (%)**
Operating revenue	40,448,399,399.41	46,006,732,392.56	-12.08
Net profit attributable to shareholders of the listed company	1,038,075,670.94	1,126,353,068.85	-7.84
Net profit after deduction of non-recurring profit or loss attributable to shareholders of listed company	983,382,470.25	1,039,747,285.77	-5.42
Weighted average return on net assets (%)	2.46	2.85	Decreased by 0.39 percentage point
Basic earnings per share (RMB per share)	0.37	0.40	-7.84
Diluted earnings per share (RMB per share)	0.37	0.40	-7.84

Non-recurring profit or loss items and amounts

✓Applicable ☐Not applicable

Unit: RMB

Items	Amount for the current period
Profit or loss on disposal of non-current assets	8,340,209.17
Government grants recognised in profit or loss for the current period excluding those closely related to the Company's ordinary operations and granted on an ongoing basis under the national policies according to certain fixed quota of amount or volume	81,425,861.87
Except for the effective hedging activities related to the Company's ordinary operations, profit or loss arising from changes in fair value of financial assets held for trading, derivative financial assets, financial liabilities held for trading, and derivative financial liabilities, and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments	14,161,800.48
Reversal of provisions on impairment of receivables and contract assets assessed for impairment on an individual basis	4,476,824.00
Other non-operating income and expenses other than the aforesaid items	-26,252,794.75
Effect on minority interests (after tax)	-10,052,126.18
Effect on income tax	-17,406,573.90
Total	54,693,200.69

2.2 The aggregate number of shareholders and shareholdings of top ten shareholders and top ten shareholders of circulating Shares (or shareholders holding Shares without trade restrictions) as at the end of the Reporting Period

Unit: Share

Aggregate number of shareholders			117,788			
Shareholdings of top ten shareholders						
				Pledged or frozen		
Name of shareholder (in full)	**Number of shares held at the end of the Reporting Period**	**Shareholding percentage (%)**	**Number of trade-restricted Shares held**	**Status of Shares**	**Number of Shares**	**Nature of shareholder**
HKSCC NOMINEES LIMITED[Note1]	832,077,124	29.277	0	Unknown		Foreign entity
Shanghai Pharmaceutical (Group)	716,516,039	25.211	0	Nil		State-owned legal person
SIIC and its wholly-owned subsidiaries and Shanghai Shangshi	289,806,498	10.197	0	Unknown		State-owned legal person and foreign entity
China Securities Finance Corporation Limited	85,333,703	3.002	0	Nil		Unknown
Hong Kong Securities Clearing Company Limited	47,655,189	1.677	0	Unknown		Foreign entity
Shanghai Guosheng and Shanghai Shengrui	43,100,900	1.517	0	Unknown		State-owned legal person
Central Huijin Asset Management Co., Ltd.	24,891,300	0.876	0	Nil		Unknown
NSSF 604 Combination	24,496,006	0.862	0	Nil		Unknown
Yinhua Fund – Agricultural Bank – Yinhua China Securities Financial Assets Management Program	11,964,367	0.421	0	Nil		Unknown
NSSF 412 Combination	11,262,800	0.396	0	Nil		Unknown

Shareholdings of top ten shareholders without trade restrictions			
Name of shareholder	**Number of Shares in circulation without trade restrictions**	**Class and number of Shares**	
		Class	**Number**
HKSCC NOMINEES LIMITED[1]	832,077,124	Overseas listed foreign shares	832,077,124
Shanghai Pharmaceutical (Group)	716,516,039	RMB ordinary shares	716,516,039
SIIC and its wholly-owned subsidiaries and Shanghai Shangshi	289,806,498	RMB ordinary shares	222,301,798
		Overseas listed foreign shares	67,504,700
China Securities Finance Corporation Limited	85,333,703	RMB ordinary shares	85,333,703
Hong Kong Securities Clearing Company Limited[2]	47,655,189	RMB ordinary shares	47,655,189
Shanghai Guosheng and Shanghai Shengrui	43,100,900	RMB ordinary shares	24,585,800
		Overseas listed foreign shares	18,515,100
Central Huijin Asset Management Co., Ltd.	24,891,300	RMB ordinary shares	24,891,300
NSSF 604 Combination	24,496,006	RMB ordinary shares	24,496,006
Yinhua Fund–Agricultural Bank – Yinhua China Securities Financial Assets Management Program	11,964,367	RMB ordinary shares	11,964,367
NSSF 412 Combination	11,262,800	RMB ordinary shares	11,262,800
Note on connected relations or concerted actions of the above shareholders	SIIC is the de facto controller of Shanghai Shangshi, which is a controlling shareholder of Shanghai Pharmaceutical (Group). Shanghai Guosheng is a wholly-owned subsidiary of Shanghai State-owned Assets Supervision and Administration Commission. Shanghai Shengrui is a wholly-owned subsidiary of Shanghai Guosheng. The Company is not aware of any affiliation among other shareholders or whether they are persons acting in concert as stipulated under the “Administrative Measures on Disclosure of Changes in Shareholders’ Shareholdings in Listed Companies”.		
Note on shareholders of preference Shares with voting rights restored and number of shares held	/		

Notes:

1 Shares held by HKSCC NOMINEES LIMITED are held on behalf of its clients and the number of Shares it holds as shown in the table above excludes the 67,504,700 H Shares held by SIIC and its wholly-owned subsidiaries and 18,515,100 H Shares held by Shanghai Guosheng and Shanghai Shengrui through Southbound Trading. As the relevant rules of the Hong Kong Stock Exchange do not require clients to report whether the shares that they hold are pledged or frozen, HKSCC NOMINEES LIMITED is unable to provide statistics on the number of shares that have been pledged or frozen;

2 Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

2.3 The aggregate number of preference shareholders, and the shareholding status of top ten preference shareholders and top ten shareholders holding preference shares without trade restrictions as of the end of the Reporting Period

☐Applicable ✓Not applicable

III. SIGNIFICANT EVENTS

3.1 Details of and reasons for material changes in major accounting items and financial indicators of the Company

✓Applicable ☐Not applicable

Consolidated balance sheet items	31 March 2020	31 December 2019	Change	Reason for change
Financial assets held for trading	700,000,000.00		/	Increase in financial assets held for trading during the Reporting Period
Derivative financial assets	8,396,104.75	3,027,011.42	177.37%	Increase in fair value of financial assets measured at fair value during the Reporting Period
Advances to suppliers	3,706,055,466.86	1,937,456,121.28	91.28%	Increase in prepayments for goods during the Reporting Period
Other non-current assets	1,537,594,567.17	3,267,487,855.84	-52.94%	Decrease in prepayments for acquisition of interests during the Reporting Period
Derivative financial liabilities		1,724,460.87	/	Decrease in fair value of financial liabilities measured at fair value during the Reporting Period
Contract liabilities	1,041,059,843.82	1,534,199,122.71	-32.14%	Decrease in advances for goods during the Reporting Period
Employee benefits payable	695,001,378.79	1,090,856,663.84	-36.29%	Increase in the payment of employee benefits during the Reporting Period
Taxes payable	589,081,959.40	1,215,420,806.49	-51.53%	Increase in taxes paid during the Reporting Period
Other current liabilities	2,500,000,000.00		/	Increase in issuance of short-term bonds during the Reporting Period

Consolidated income statement items	January to March 2020	Amount for the same period of previous year	Change	Reason for change
Other income	94,949,743.39	69,457,450.69	36.70%	Increase in government grants obtained during the Reporting Period
Gains from changes in fair value	12,735,133.82	-1,540,603.07	/	Increase in fair value of financial instruments during the Reporting Period
Credit impairment losses	116,831,499.82	41,762,608.23	179.75%	Increase in provisions for impairment of financial assets during the Reporting Period
Asset impairment losses	34,585,837.34	6,282,655.23	450.50%	Increase in provisions for impairment of inventory provision during the Reporting Period
Gains from assets disposal	-355,281.32	7,657,012.40	/	Decrease in gains from disposal of long-term assets during the Reporting Period
Non-operating income	8,377,341.39	75,956,121.66	-88.97%	Decrease in relocation compensation received during the Reporting Period
Non-operating expenses	34,630,136.14	17,993,897.76	92.45%	Increase in donation expenses during the Reporting Period
Consolidated cash flow statement items	**January to March 2020**	**Amount for the same period of previous year**	**Change**	**Reason for change**
Net cash flows from operating activities	-592,090,019.55	153,660,971.11	/	Increase in payment for goods during the Reporting Period
Net cash flows from investing activities	692,960,108.61	-766,738,802.91	/	Increase in cash held for acquisition of subsidiaries during the Reporting Period
Net cash flows from financing activities	3,866,200,750.04	637,218,503.97	506.73%	Increase in cash received from issuance of short-term bonds during the Reporting Period

3.2 Progress of major events and their effects and analysis of solutions

☐Applicable ✓Not applicable

3.3 Commitment overdue and unfulfilled during the Reporting Period

☐Applicable ✓Not applicable

3.4 Warning in respect of the forecast of a probable loss or a significant change as compared with that of the corresponding period of previous year in the accumulated net profit from the beginning of the year to the end of the next reporting period and its reasons

☐Applicable ✓Not applicable

Name of the Company	**Shanghai Pharmaceuticals Holding Co., Ltd.**
Legal representative	**ZHOU Jun**
Date	**28 April 2020**

IV. APPENDICES

4.1 Financial Statements

CONSOLIDATED BALANCE SHEET

31 March 2020

Name of enterprise: Shanghai Pharmaceuticals Holding Co., Ltd.

Unit: RMB   Type of Audit: Unaudited

Items	**31 March 2020**	**31 December 2019**
Current assets:		
Monetary funds	21,718,515,898.49	18,152,817,741.94
Deposit reservation for balance		
Lending funds		
Financial assets held for trading	700,000,000.00	
Derivative financial assets	8,396,104.75	3,027,011.42
Notes receivable	263,529,998.39	274,119,544.70
Accounts receivable	45,861,437,075.87	47,339,803,537.21
Financing receivable	1,762,100,843.68	2,187,059,525.49
Advances to suppliers	3,706,055,466.86	1,937,456,121.28
Premiums receivable		
Reinsurance accounts receivable		
Receivable from subcontracting reserves		
Other receivables	2,072,200,175.94	2,202,960,796.71
Including: Interests receivable		
Dividends receivable	1,446,375.00	49,737,611.50
Redemptory monetary capital for sale		
Inventories	26,051,208,774.59	24,877,356,781.61
Contract assets		
Assets classified as held for sale		
Non-current assets due within one year	22,329,191.51	23,257,721.60
Other current assets	1,163,865,493.72	1,093,722,591.66
Total current assets	103,329,639,023.80	98,091,581,373.62

Items	31 March 2020	31 December 2019
Non-current assets:		
Issuing of loans and advances		
Debt investments		
Other debt investments		
Long-term receivables	270,239,223.37	265,642,096.94
Long-term equity investments	4,852,333,054.17	4,853,779,059.53
Investments in other equity instruments	144,120,800.69	194,183,980.82
Other non-current financial assets	393,171,978.51	384,398,172.73
Investment properties	238,674,745.28	292,319,211.54
Fixed assets	9,917,704,642.67	9,445,675,117.04
Construction in progress	1,329,324,283.23	1,649,896,366.49
Bearer biological assets	412,865,689.18	410,145,018.27
Oil-and-gas assets		
Right-of-use assets	1,552,030,994.75	1,622,096,400.05
Intangible assets	3,826,201,036.34	3,930,371,809.89
Development disbursement	213,957,675.65	211,593,325.81
Goodwill	11,660,979,353.98	10,789,918,517.77
Long-term prepaid expenses	375,808,744.20	394,799,913.53
Deferred income tax assets	1,228,168,214.08	1,222,507,639.85
Other non-current assets	1,537,594,567.17	3,267,487,855.84
Total non-current assets	37,953,175,003.27	38,934,814,486.10
Total assets	141,282,814,027.07	137,026,395,859.72

Items	31 March 2020	31 December 2019
Current liabilities:		
Short-term borrowings	25,086,963,057.32	23,138,687,189.75
Borrowing from the Central Bank		
Borrowing funds		
Financial liabilities held for trading		
Derivative financial liabilities		1,724,460.87
Bills payable	4,578,170,407.85	5,053,473,408.54
Accounts payable	31,468,549,491.65	31,818,985,528.48
Advances from customers		
Contract liabilities	1,041,059,843.82	1,534,199,122.71
Financial assets sold for repurchase		
Absorbing deposit and interbank deposit		
Receivings from vicariously traded securities		
Receivings from vicariously sold securities		
Employee benefits payable	695,001,378.79	1,090,856,663.84
Taxes payable	589,081,959.40	1,215,420,806.49
Other payables	9,739,351,628.04	9,565,692,034.58
Including: Interests payable		
Dividends payable	183,542,703.31	99,519,576.04
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities classified as held for sale		
Non-current liabilities due within one year	1,198,637,159.45	1,188,602,322.14
Other current liabilities	2,500,000,000.00	
Total current liabilities	76,896,814,926.32	74,607,641,537.40

Items	31 March 2020	31 December 2019
Non-current liabilities:		
Provision for insurance contracts		
Long-term borrowings	6,215,559,392.40	6,135,992,761.69
Bonds payable	2,998,467,606.42	2,998,228,732.34
Including: Preference shares		
Perpetual bonds		
Lease liabilities	1,104,024,473.83	1,155,638,865.78
Long-term payables	385,397,947.79	415,627,976.40
Long-term employee benefits payable	48,612,697.64	48,095,893.55
Accrued liabilities	70,923,169.00	70,923,169.00
Deferred income	1,315,054,490.71	1,278,726,271.79
Deferred income tax liabilities	751,567,691.45	809,599,134.48
Other non-current liabilities	107,072,636.31	119,993,223.89
Total non-current liabilities	12,996,680,105.55	13,032,826,028.92
Total liabilities	89,893,495,031.87	87,640,467,566.32
Owners' equity (or shareholders' equity):		
Paid-up capital (or share capital)	2,842,089,322.00	2,842,089,322.00
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserves	15,729,245,402.88	15,720,601,835.88
Less: Treasury shares		
Other comprehensive income	-633,542,865.60	-542,229,067.12
Special reserves		
Surplus reserves	1,667,684,535.82	1,667,684,535.82
General risk provisions		
Undistributed profits	23,010,950,092.58	21,970,908,120.34
Total owners' equity (or shareholders' equity) attributable to the parent company	42,616,426,487.68	41,659,054,746.92
Minority interests	8,772,892,507.52	7,726,873,546.48
Total owners' equity (or shareholders' equity)	51,389,318,995.20	49,385,928,293.40
Total liabilities and owners' equity (or shareholders' equity)	141,282,814,027.07	137,026,395,859.72

Legal representative: ZHOU Jun The principal in charge of accounting: CHO Man
Head of accounting department: SHEN Bo

BALANCE SHEET OF THE PARENT COMPANY

31 March 2020

Name of enterprise: Shanghai Pharmaceuticals Holding Co., Ltd.

Unit: RMB Type of Audit: Unaudited

Items	31 March 2020	31 December 2019
Current assets:		
Monetary funds	4,646,145,429.86	3,688,306,798.50
Financial assets held for trading	700,000,000.00	
Derivative financial assets		
Notes receivable		
Accounts receivable		
Financing receivable		
Advances to suppliers	2,823,605.50	482,514.35
Other receivables	19,307,968,348.11	16,676,400,517.51
Including: Interests receivable		
Dividends receivable	787,710,403.58	786,704,488.65
Inventories		
Contract assets		
Assets classified as held for sale		
Non-current assets due within one year		
Other current assets		
Total current assets	24,656,937,383.47	20,365,189,830.36

Items	31 March 2020	31 December 2019
Non-current assets:		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments	22,602,286,566.87	22,508,236,186.23
Investments in other equity instruments		
Other non-current financial assets	25,206,737.80	25,206,737.80
Investment properties		
Fixed assets	55,630,039.39	55,394,368.16
Construction in progress	17,640,929.64	17,811,606.35
Bearer biological assets		
Oil-and-gas assets		
Right-of-use assets	3,237,624.76	5,485,517.64
Intangible assets	85,753,913.28	90,518,114.22
Development disbursement		
Goodwill		
Long-term prepaid expenses	1,432,215.60	901,352.01
Deferred income tax assets		
Other non-current assets	2,939,521.44	1,535,681.44
Total non-current assets	22,794,127,548.78	22,705,089,563.85
Total assets	47,451,064,932.25	43,070,279,394.21

Items	31 March 2020	31 December 2019
Current liabilities:		
Short-term borrowings	2,702,642,465.28	2,703,229,875.00
Financial liabilities held for trading		
Derivative financial liabilities		
Bills payable		
Accounts payable	44,188,059.21	20,852,915.38
Advances from customers		
Contract liabilities	4,215,189.17	4,207,189.17
Employee benefits payable	19,264,993.37	43,277,332.24
Taxes payable	10,357,502.30	10,500,289.31
Other payables	13,188,144,673.14	11,442,314,213.85
Including: Interests payable		
Dividends payable		
Liabilities classified as held for sale		
Non-current liabilities due within one year	57,581,685.01	23,996,517.76
Other current liabilities	2,500,000,000.00	
Total current liabilities	18,526,394,567.48	14,248,378,332.71
Non-current liabilities:		
Long-term borrowings		
Bonds payable	2,998,467,606.42	2,998,228,732.34
Including: Preference shares		
Perpetual bonds		
Lease liabilities		
Long-term payables		
Long-term employee benefits payable		
Accrued liabilities		
Deferred income	41,569,093.06	43,131,349.85
Deferred income tax liabilities	5,859,736.77	5,859,736.77
Other non-current liabilities		
Total non-current liabilities	3,045,896,436.25	3,047,219,818.96
Total liabilities	21,572,291,003.73	17,295,598,151.67

Items	**31 March 2020**	**31 December 2019**
Owners' equity (or shareholders' equity):		
Paid-up capital (or share capital)	2,842,089,322.00	2,842,089,322.00
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserves	18,856,501,874.71	18,847,858,307.71
Less: Treasury shares		
Other comprehensive income	-1,501,202.91	-1,509,389.95
Special reserves		
Surplus reserves	1,296,575,310.72	1,296,575,310.72
Undistributed profits	2,885,108,624.00	2,789,667,692.06
Total owners' equity (or shareholders' equity)	25,878,773,928.52	25,774,681,242.54
Total liabilities and owners' equity (or shareholders' equity)	47,451,064,932.25	43,070,279,394.21

Legal representative: ZHOU Jun The principal in charge of accounting: CHO Man
Head of accounting department: SHEN Bo

CONSOLIDATED INCOME STATEMENT

January to March 2020

Name of enterprise: Shanghai Pharmaceuticals Holding Co., Ltd.

Unit: RMB Type of Audit: Unaudited

Items	The first quarter of 2020	The first quarter of 2019
I. Total revenue of operation	40,448,399,399.41	46,006,732,392.56
Including: Operating revenue	40,448,399,399.41	46,006,732,392.56
Interest income		
Earned premium		
Service charges and commission income		
II. Total cost of operation	39,063,164,783.40	44,579,761,762.18
Including: Cost of operation	34,195,816,964.77	39,402,640,643.25
Interest payments		
Service charges and commission fee		
Surrender charge fee		
Net payments for insurance claims		
Extraction of insurance obligations net reserves		
Policyholder dividend expenses		
Reinsurance expenses		
Business taxes and surcharges	114,734,441.78	137,983,654.49
Selling expenses	2,940,182,319.95	3,313,673,696.55
Administrative expenses	1,116,068,782.19	1,153,208,386.31
R&D expenses	341,266,643.74	270,986,905.84
Financial expenses	355,095,630.97	301,268,475.74
Including: Interest expenses	375,295,379.35	358,697,093.82

Items	The first quarter of 2020	The first quarter of 2019
Interest income	74,615,802.97	65,691,211.84
Add: Other income	94,949,743.39	69,457,450.69
Investment income (loss indicated by "–")	251,770,238.82	206,071,669.43
Including: Share of investment profit of associates and joint ventures	266,788,878.08	235,827,351.04
Derecognition gains on financial assets measured at amortised cost	-6,708,187.45	-2,759,324.98
Exchange earnings (loss indicated by "–")		
Net gains from hedging exposure (loss indicated by "–")		
Gains arising from changes in fair value (loss indicated by "–")	12,735,133.82	-1,540,603.07
Credit impairment loss (loss indicated by "–")	-116,831,499.82	-41,762,608.23
Asset impairment loss (loss indicated by "–")	-34,585,837.34	-6,282,655.23
Gains on assets disposal (loss indicated by "–")	-355,281.32	7,657,012.40
III. Operating profit (loss indicated by "–")	1,592,917,113.56	1,660,570,896.37
Add: Non-operating income	8,377,341.39	75,956,121.66
Less: Non-operating expenses	34,630,136.14	17,993,897.76
IV. Total profit (total loss indicated by "–")	1,566,664,318.81	1,718,533,120.27
Less: Income tax expenses	338,902,584.44	342,994,658.05
V. Net profit (net loss indicated by "–")	1,227,761,734.37	1,375,538,462.22
(1) Classified on a going concern basis		
1. Net profit from continuing operations (net loss indicated by "–")	1,227,761,734.37	1,375,538,462.22
2. Net profit from discontinued operations (net loss indicated by "–")		
(2) Classified according to the ownership		
1. Net profit attributable to shareholders of the parent company (net loss indicated by "–")	1,038,075,670.94	1,126,353,068.85

Items	**The first quarter of 2020**	**The first quarter of 2019**
2. Minority interests (net loss indicated by "–")	189,686,063.43	249,185,393.37
VI. Other comprehensive income, net of tax	-98,039,397.18	106,193,160.49
(I) Other comprehensive income attributable to owners of the parent company, net of tax	-91,313,798.48	49,945,648.76
1. Other comprehensive income that will not be reclassified to profit or loss	-8,295,244.96	24,597,959.75
(1) Changes in the re-measurement of defined benefit plans		
(2) Other comprehensive income accounted for using equity method, which will not be reclassified to profit or loss		
(3) Changes in fair value of investments in other equity instruments	-8,295,244.96	24,597,959.75
(4) Changes in fair value arising from the enterprise's credit risk		
2. Other comprehensive income that will be reclassified to profit or loss	-83,018,553.52	25,347,689.01
(1) Other comprehensive income accounted for using equity method, which will be reclassified to profit or loss	12,330.05	
(2) Changes in fair value of other debt investments		
(3) Other comprehensive income arising from reclassifying financial assets		
(4) Provision for credit impairment of other debt investments		
(5) Cash flow hedging reserve		
(6) Exchange differences on translation of financial statements denominated in foreign currencies	-84,193,932.65	25,347,689.01
(7) Others	1,163,049.08	

Items	The first quarter of 2020	The first quarter of 2019
(II) Other comprehensive income attributable to minority shareholders, net of tax	-6,725,598.70	56,247,511.73
VII. Total comprehensive income	1,129,722,337.19	1,481,731,622.71
(I) Total comprehensive income attributable to owners of the parent company	946,761,872.46	1,176,298,717.61
(II) Total comprehensive income attributable to minority shareholders	182,960,464.73	305,432,905.10
VIII. Earnings per share		
(I) Basic earnings per share (RMB/share)	0.37	0.40
(II) Diluted earnings per share (RMB/share)	0.37	0.40

For business combination involving enterprises under common control during this Period, the net profit realized by the acquiree before the business combination is RMB0 as compared to RMB0 for the last period.

Legal representative: ZHOU Jun The principal in charge of accounting: CHO Man
Head of accounting department: SHEN Bo

INCOME STATEMENT OF THE PARENT COMPANY

January to March 2020

Name of enterprise: Shanghai Pharmaceuticals Holding Co., Ltd.

Unit: RMB Type of Audit: Unaudited

Items	**The first quarter of 2020**	**The first quarter of 2019**
I. Operating revenue	4,341,973.58	428,266.23
Less: Cost of operation	235,676.32	
Business taxes and surcharges	1,320.00	1,440.00
Selling expenses		
Administrative expenses	42,411,113.18	38,928,370.64
R&D expenses	81,822,533.68	31,113,938.23
Financial expenses	10,539,283.20	101,989,716.81
Including: Interest expenses	67,957,800.39	59,655,767.16
Interest income	4,512,026.32	3,001,768.09
Add: Other income	700,256.79	790,473.25
Investment income (loss indicated by "–")	226,308,627.95	107,988,105.44
Including: Share of investment profit of associates and joint ventures	60,059,593.61	29,639,405.96
Derecognition gains on financial assets measured at amortised cost		
Net gains from hedging exposure (loss indicated by "–")		
Gains arising from changes in fair value (loss indicated by "–")		
Credit impairment losses (loss indicated by "–")		
Asset impairment losses (loss indicated by "–")		
Gains on assets disposal (loss indicated by "–")		

Items	The first quarter of 2020	The first quarter of 2019
II. Operating profit (loss indicated by "–")	96,340,931.94	-62,826,620.76
Add: Non-operating income		
Less: Non-operating expenses	900,000.00	
III. Total profit (total loss indicated by "–")	95,440,931.94	-62,826,620.76
Less: Income tax expenses		
IV. Net profit (net loss indicated by "–")	95,440,931.94	-62,826,620.76
(I) Net profit from continuing operations (net loss indicated by "–")	95,440,931.94	-62,826,620.76
(II) Net profit from discontinued operations (net loss indicated by "–")		
V. Other comprehensive income, net of tax	8,187.04	
(I) Other comprehensive income that will not be reclassified to profit or loss		
1. Changes in the re-measurement of defined benefit plans		
2. Other comprehensive income accounted for using equity method, which will not be reclassified to profit or loss		
3. Changes in fair value of investments in other equity instruments		
4. Changes in fair value arising from the enterprise's credit risk		

Items	The first quarter of 2020	The first quarter of 2019
(II) Other comprehensive income that will be reclassified to profit or loss	8,187.04	
1. Other comprehensive income accounted for using equity method, which will be reclassified to profit or loss	8,187.04	
2. Changes in fair value of other debt investments		
3. Other comprehensive income arising from reclassifying financial assets		
4. Provision for credit impairment of other debt investments		
5. Cash flow hedging reserve		
6. Exchange differences on translation of financial statements denominated in foreign currencies		
7. Others		
VI. Total comprehensive income	95,449,118.98	-62,826,620.76
VII. Earnings per share		
(I) Basic earnings per share (RMB/share)	N/A	N/A
(II) Diluted earnings per share (RMB/share)	N/A	N/A

Legal representative: ZHOU Jun The principal in charge of accounting: CHO Man
Head of accounting department: SHEN Bo

CONSOLIDATED CASH FLOW STATEMENT

January to March 2020

Name of enterprise: Shanghai Pharmaceuticals Holding Co., Ltd.

Unit: RMB Type of Audit: Unaudited

Items	The first quarter of 2020	The first quarter of 2019
I. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	46,220,683,332.00	46,773,261,150.31
Net increase in customer deposits and interbank deposit payment		
Net increase in borrowing from the Central Bank		
Net increase in funds borrowed from other financial institutions		
Cash received from the receipt of the original insurance contract premiums		
Net cash received from reinsurance business		
Net increase in deposit of the insured and investment fund		
Interest, fees and commission in cash		
Net increase in funds borrowed		
Net increase in capital for repurchase business		
Net cash received from customer for acting as securities trading agent		
Refund of taxes received	21,310,267.07	19,381,317.97
Cash received relating to other operating activities	807,830,981.28	335,481,404.07
Subtotal of cash inflows from operating activities	47,049,824,580.35	47,128,123,872.35
Cash paid for goods and services	41,521,110,052.08	41,545,755,507.34
Net increase in customer loans and advances		
Net increase in placements with the Central Bank and Interbank		
Cash paid for claims on original insurance contract		
Net increase in lending funds		

Items	The first quarter of 2020	The first quarter of 2019
Cash paid for interest, fees and commissions		
Cash paid for policy dividend		
Cash paid to and on behalf of employees	1,975,742,753.03	1,934,711,918.39
Payments of taxes	1,614,269,487.91	1,788,845,038.86
Cash paid relating to other operating activities	2,530,792,306.88	1,705,150,436.65
Subtotal of cash outflows from operating activities	47,641,914,599.90	46,974,462,901.24
Net cash flows from operating activities	-592,090,019.55	153,660,971.11
II. Cash flows from investing activities:		
Cash received from disposal of investments	45,409,084.24	301,116,330.50
Cash received from returns on investments	100,544,957.56	15,215,601.82
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	547,431.89	3,037,881.89
Net cash received from disposal of subsidiaries and other business units	71,397,888.56	
Cash received relating to other investing activities	2,364,342,709.33	3,559,999.92
Subtotal of cash inflows from investing activities	2,582,242,071.58	322,929,814.13
Cash paid to acquire fixed assets, intangible assets and other long-term assets	742,006,121.63	412,806,988.53
Cash paid to acquire investments	700,000,000.00	299,903,998.00
Net increase in pledged loans		
Net cash paid to acquire subsidiaries and other business units	315,428,644.00	360,281,630.51
Cash paid relating to other investing activities	131,847,197.34	16,676,000.00
Subtotal of cash outflows from investing activities	1,889,281,962.97	1,089,668,617.04
Net cash flows from investing activities	692,960,108.61	-766,738,802.91

Items	The first quarter of 2020	The first quarter of 2019
III. Cash flows from financing activities:		
Cash received from capital contributions		490,000.00
Including: Cash received from capital contributions of minority shareholders of subsidiaries		490,000.00
Cash received from borrowings	15,663,429,022.00	12,553,391,195.50
Cash received from issue of bonds	2,498,125,000.00	
Cash received relating to other financing activities	248,461,031.29	205,000,000.00
Subtotal of cash inflows from financing activities	18,410,015,053.29	12,758,881,195.50
Cash paid for repayments of debts	13,562,334,331.84	11,573,111,044.96
Cash paid for distribution of dividends, profits or interest payment	832,679,506.04	368,582,495.03
Including: Dividends and profits paid to minority shareholders by subsidiaries	456,314,206.35	29,320,732.02
Cash paid relating to other financing activities	148,800,465.37	179,969,151.54
Subtotal of cash outflows from financing activities	14,543,814,303.25	12,121,662,691.53
Net cash flows from financing activities	3,866,200,750.04	637,218,503.97
IV. Effect of foreign exchange rate changes on cash and cash equivalents	307,136.02	-12,970,125.67
V. Net increase in cash and cash equivalents	3,967,377,975.12	11,170,546.50
Add: Balance of cash and cash equivalents at the beginning of the Period	15,716,257,907.41	16,605,554,712.49
VI. Balance of cash and cash equivalents at the end of the Period	19,683,635,882.53	16,616,725,258.99

Legal representative: ZHOU Jun The principal in charge of accounting: CHO Man
Head of accounting department: SHEN Bo

CASH FLOW STATEMENT OF THE PARENT COMPANY

January to March 2020

Name of enterprise: Shanghai Pharmaceuticals Holding Co., Ltd.

Unit: RMB Type of Audit: Unaudited

Items	**The first quarter of 2020**	**The first quarter of 2019**
I. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	442,420.90	453,962.20
Refund of taxes received		
Cash received relating to other operating activities	33,055,267.52	63,300,223.55
Subtotal of cash inflows from operating activities	33,497,688.42	63,754,185.75
Cash paid for goods and services		6,512,111.68
Cash paid to and on behalf of employees	53,692,010.73	44,355,904.45
Payments of taxes	3,427,978.12	169,173.11
Cash paid relating to other operating activities	97,184,585.35	56,508,287.44
Subtotal of cash outflows from operating activities	154,304,574.20	107,545,476.68
Net cash flows from operating activities	-120,806,885.78	-43,791,290.93
II. Cash flows from investing activities:		
Cash received from disposal of investments		301,116,330.50
Cash received from returns on investments	82,175,000.00	297,459,544.33
Net cash received from disposal of fixed assets, intangible assets and other long-term assets		
Net cash received from disposal of subsidiaries and other business units		
Cash received relating to other investing activities	1,010,205,843.67	4,486,725,625.77
Subtotal of cash inflows from investing activities	1,092,380,843.67	5,085,301,500.60
Cash paid to acquire fixed assets, intangible assets and other long-term assets	7,858,860.13	5,522,503.20
Cash paid to acquire investments	700,000,000.00	3,065,903,998.00
Net cash paid to acquire subsidiaries and other business units	20,000,000.00	
Cash paid relating to other investing activities	2,826,177,196.16	1,514,272,800.00
Subtotal of cash outflows from investing activities	3,554,036,056.29	4,585,699,301.20
Net cash flows from investing activities	-2,461,655,212.62	499,602,199.40

Items	The first quarter of 2020	The first quarter of 2019
III. Cash flows from financing activities:		
Cash received from capital contributions		
Cash received from borrowings	2,700,000,000.00	2,700,000,000.00
Cash received from issue of bonds	2,498,125,000.00	
Cash received relating to other financing activities	1,074,914,795.68	190,000,000.00
Subtotal of cash inflows from financing activities	6,273,039,795.68	2,890,000,000.00
Cash paid for repayments of debts	2,700,000,000.00	2,600,000,000.00
Cash paid for distribution of dividends, profits or interest payment	30,311,697.59	23,138,365.32
Cash paid relating to other financing activities	2,511,984.00	59,600,000.00
Subtotal of cash outflows from financing activities	2,732,823,681.59	2,682,738,365.32
Net cash flows from financing activities	3,540,216,114.09	207,261,634.68
IV. Effect of foreign exchange rate changes on cash and cash equivalents	84,615.67	-105,662.25
V. Net increase in cash and cash equivalents	957,838,631.36	662,966,880.90
Add: Balance of cash and cash equivalents at the beginning of the Period	3,398,271,917.33	1,617,374,798.30
VI. Balance of cash and cash equivalents at the end of the Period	4,356,110,548.69	2,280,341,679.20

Legal representative: ZHOU Jun The principal in charge of accounting: CHO Man
Head of accounting department: SHEN Bo

4.2 Particulars in relation to adjustments made to the financial statements as at the beginning of the year of the initial adoption of the New Revenue Standard and the New Lease Standard in 2020

☐Applicable ✓Not applicable

4.3 Description of the retrospective adjustment to the comparable figures for the previous period due to the initial adoption of the New Revenue Standard and the New Lease Standard in 2020

☐Applicable ✓Not applicable

4.4 Audit Report

☐Applicable ✓Not applicable